http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109239210-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-02 |
| filingDate | 2018-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109239210-B |
| titleOfInvention | A kind of ductal adenocarcinoma of pancreas marker and its screening technique |
| abstract | A kind of ductal adenocarcinoma of pancreas marker and its screening technique, belong to clinical examination diagnostic field.Aiming at the problem that diagnosis marker detection sensitivity and poor specificity of current ductal adenocarcinoma of pancreas, the present invention carries out micro metabonomic analysis to early stage ductal adenocarcinoma of pancreas early stage patient serum by high performance liquid chromatography-tandem mass technology, finds the difference metabolin between normal population and early stage ductal adenocarcinoma of pancreas crowd；The difference metabolin between normal person and ductal adenocarcinoma of pancreas patient is further analyzed by the technology；Find the specific difference metabolite C10:1 fatty acyl carnitine and lysophosphatidyl choline LysoPC (14:0) of ductal adenocarcinoma of pancreas patient caused by cancer, i.e. the diagnosis molecule of ductal adenocarcinoma of pancreas.CA19-9 Diagnosis of Pancreatic duct adenocarcinoma crowd can be assisted, the diagnosis of CA19-9 negative patient 85% can be improved.The present invention is suitable for the screening of tumor markers. |
| priorityDate | 2018-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 108.